DEXCOM INC — Director's Dealing 2022

Mar 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2022-03-08

Reporting Person: Shrishrimal Sumi (SVP Chief Risk Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-08	Common Stock	A	2889	$0.001	Acquired	15146	Direct
2022-03-09	Common Stock	D	519	$406.0567	Disposed	14627	Direct
2022-03-09	Common Stock	D	192	$406.0567	Disposed	14435	Direct
2022-03-09	Common Stock	D	309	$406.0567	Disposed	14126	Direct
2022-03-09	Common Stock	D	337	$406.0567	Disposed	13789	Direct

Footnotes

F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2: Included in this number are 6,373 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,436 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.